Reuters logo
BRIEF-Glycomimetics presents updated data from ongoing phase 1/2 clinical trial of GMI-1271 at ASCO
2017年6月5日 / 上午11点17分 / 5 个月前

BRIEF-Glycomimetics presents updated data from ongoing phase 1/2 clinical trial of GMI-1271 at ASCO

June 5 (Reuters) - Glycomimetics Inc

* Glycomimetics presents updated data from ongoing phase 1/2 clinical trial of GMI-1271 in patients with acute myeloid leukemia at ASCO 2017 annual meeting

* Glycomimetics Inc says GMI-1271 continues to be well tolerated in combination with induction chemotherapy

* Glycomimetics -remission rates continue to be higher than historical controls & induction-related mortality continues to be lower than historical controls

* Glycomimetics Inc - in study only one case of severe (grade 3/4) mucositis reported among 79 patients receiving high-intensity induction chemotherapy

* Glycomimetics Inc - relapsed/refractory patients with more blasts expressing e-selectin ligand were more likely to achieve complete response in study Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below